Brokerages Set Kymera Therapeutics, Inc. (NASDAQ:KYMR) Target Price at $56.36

Shares of Kymera Therapeutics, Inc. (NASDAQ:KYMR) have earned an average rating of “Moderate Buy” from the fifteen brokerages that are currently covering the company, MarketBeat Ratings reports. Three investment analysts have rated the stock with a hold recommendation, eleven have issued a buy recommendation and one has issued a strong buy recommendation on the company. The average 1 year price objective among brokerages that have issued a report on the stock in the last year is $56.36.

Several research analysts have recently weighed in on the stock. BMO Capital Markets began coverage on shares of Kymera Therapeutics in a report on Friday, December 6th. They set a “market perform” rating and a $55.00 price objective for the company. Leerink Partners reiterated an “outperform” rating and set a $60.00 target price on shares of Kymera Therapeutics in a research note on Friday, December 27th. BTIG Research initiated coverage on Kymera Therapeutics in a research note on Tuesday, December 10th. They issued a “buy” rating and a $60.00 price target on the stock. Stephens reaffirmed an “overweight” rating and issued a $60.00 price objective on shares of Kymera Therapeutics in a report on Tuesday, January 21st. Finally, Wells Fargo & Company raised Kymera Therapeutics from an “equal weight” rating to an “overweight” rating and increased their target price for the company from $38.00 to $57.00 in a report on Monday, December 2nd.

Insider Activity

In other Kymera Therapeutics news, COO Jeremy G. Chadwick sold 1,383 shares of Kymera Therapeutics stock in a transaction on Monday, March 3rd. The stock was sold at an average price of $30.45, for a total value of $42,112.35. Following the sale, the chief operating officer now owns 67,800 shares in the company, valued at $2,064,510. The trade was a 2.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Ellen Chiniara sold 2,241 shares of the business’s stock in a transaction dated Monday, March 3rd. The shares were sold at an average price of $30.45, for a total transaction of $68,238.45. Following the completion of the sale, the insider now owns 80,085 shares in the company, valued at approximately $2,438,588.25. This trade represents a 2.72 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 13,788 shares of company stock worth $455,202 over the last ninety days. Corporate insiders own 15.82% of the company’s stock.

Institutional Investors Weigh In On Kymera Therapeutics

A number of hedge funds have recently added to or reduced their stakes in KYMR. Blue Trust Inc. boosted its position in shares of Kymera Therapeutics by 74.8% during the 4th quarter. Blue Trust Inc. now owns 631 shares of the company’s stock worth $25,000 after acquiring an additional 270 shares in the last quarter. State of Wyoming purchased a new stake in Kymera Therapeutics during the fourth quarter worth approximately $45,000. GF Fund Management CO. LTD. acquired a new position in Kymera Therapeutics in the fourth quarter valued at approximately $55,000. KBC Group NV increased its stake in Kymera Therapeutics by 53.8% in the fourth quarter. KBC Group NV now owns 2,151 shares of the company’s stock valued at $87,000 after purchasing an additional 752 shares during the last quarter. Finally, Quarry LP acquired a new stake in Kymera Therapeutics during the third quarter worth approximately $95,000.

Kymera Therapeutics Trading Down 1.3 %

NASDAQ:KYMR opened at $34.03 on Friday. The company has a 50-day moving average price of $37.18 and a 200-day moving average price of $42.56. The stock has a market cap of $2.21 billion, a price-to-earnings ratio of -14.54 and a beta of 2.22. Kymera Therapeutics has a 12 month low of $29.07 and a 12 month high of $53.27.

Kymera Therapeutics (NASDAQ:KYMR) last posted its quarterly earnings data on Thursday, February 27th. The company reported ($0.88) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.76) by ($0.12). Kymera Therapeutics had a negative return on equity of 24.96% and a negative net margin of 191.26%. The firm had revenue of $7.39 million during the quarter, compared to the consensus estimate of $14.81 million. Equities analysts forecast that Kymera Therapeutics will post -2.79 EPS for the current fiscal year.

Kymera Therapeutics Company Profile

Kymera Therapeutics, Inc, a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors.